CG
IRD

Cutler Group’s Opus Genetics IRD Stock Holding History

Cutler Group’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed – – 5647
2022
Q2 		$0 Hold
200
– – ﹤0.01% 5822
2022
Q1 		$0 Buy
200
+100
+100% +$342 ﹤0.01% 6212
2021
Q4 		$0 Buy
+100
New +$401 ﹤0.01% 6262
2021
Q3 		– Sell
-7,900
Closed -$36.4K – 6500
2021
Q2 		$41K Buy
+7,900
New +$39.2K ﹤0.01% 2670

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Cutler Group's IRD Position: Q3 2022 in Review

Cutler Group sold out of Opus Genetics (IRD) in Q3 2022, closing a stake of 200 shares.

Cutler Group first reported a position in IRD in Q2 2021 and held it in 4 quarters. The position peaked at $41K in Q2 2021. 37 funds tracked by Wall St. Rank hold IRD as of Q3 2022.

  • Cutler Group reported no remaining Opus Genetics position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 200 Opus Genetics shares in Q3 2022.
  • Cutler Group first reported a position in Opus Genetics in Q2 2021 and held it in 4 quarters.
  • Cutler Group's Opus Genetics position peaked at $41K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.